Linked Data API

Show Search Form

Search Results

909619
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Handbooks more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how amendments to the NHS Constitution Handbook are communicated to patients. more like this
star this property tabling member printed
Lord Brooke of Alverthorpe more like this
star this property uin HL8114 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>In accordance with the Health Act 2009 we are currently reviewing the handbook that accompanies the NHS Constitution and will publish a revised version in summer 2018. As the handbook is an explanatory document, and cannot alter the NHS Constitution itself, this is a technical update that will bring the handbook up to date with policy developments since it was last published in 2015. Changes will be based largely on contributions provided from within the Department, from NHS England and from Public Health England.</p><p>As we set out in response to recommendations on National Health Service sustainability made by the House of Lords, we are looking particularly closely at the section in the handbook that explains patient responsibilities in the NHS Constitution. We will include a stronger statement about the role that patients and the public can play in supporting NHS sustainability by looking after their own health, adopting healthy behaviours, and making appropriate use of NHS resources. We will also point out where there is further information on the NHS website.</p><p>When the revised handbook is published, we will encourage NHS England, Public Health England and other stakeholders – including Healthwatch England as the independent national champion for people who use health and social care services – to promote it through their extensive networks. We will also publicise it through the NHS Constitution Twitter and Facebook accounts.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8112 more like this
HL8113 more like this
star this property question first answered
less than 2018-06-05T15:57:16.213Zmore like thismore than 2018-06-05T15:57:16.213Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
3335
unstar this property label Biography information for Lord Brooke of Alverthorpe more like this
909643
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Hepatitis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how they intend to ensure that currently under-served groups, such as people who inject drugs and those in prisons, are included in the elimination plan for hepatitis C. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL8138 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>A variety of initiatives are underway in England to improve awareness and case finding, re-engagement and linkage to care, especially in drug services, primary care, prisons and accident and emergency centres. In addition, NHS England is funding access to new hepatitis C treatments in accordance with guidance from the National Institute for Health and Care Excellence.</p><p>As part of health services commissioned for those in detained settings, NHS England has rolled out an ambitious Opt-Out Blood Borne Viruses (BBV) testing programme. The key aim is to improve uptake rates for hepatitis C testing by the introduction of good practice for ‘meaningful offer’ of BBV testing across the adult prison estate. In this programme appropriately trained staff offer prisoners a BBV testing on an opt-out basis within 72 hours of reception in accordance with published national guidance, with referral to specialists for assessment for treatment (which can be delivered in prison or on release). This programme has been embedded across the secure estate from April 2018.</p><p>The creation of 22 operational delivery networks in England to drive improvements in treatment in local areas is intended to give all patients the access to the treatment they need regardless of where they live.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-05T15:59:48.497Zmore like thismore than 2018-06-05T15:59:48.497Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
909623
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Drugs: Marketing more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what discussions they have had with the UK Medicines Verification Organisation about its policy of requiring companies who are Marketing Authorisation Holders to pay identical (1) set up, and (2) annual operational, fees regardless of the size of those companies; and what assessment they have made of the impact of that policy on the competitiveness of smaller companies. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8118 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>SecurMed, the United Kingdom’s National Medicines Verification Organisation, is responsible for the fee model and level of fees. In their supervisory capacity, the Department and the Medicines and Healthcare products Regulatory Agency have been involved in discussions with SecurMed to challenge and seek to influence the pricing model to ensure that the UK’s fee structure is fair and proportionate.</p><p>The European Commission has confirmed that the fee model being used by SecurMed is in line with the majority of other National Medicines Verification Organisations across the European Union.</p><p>However, in light of feedback on the potential impact of the proposed level of fees for smaller companies, SecurMed has announced an annual fee waiver scheme for the Marketing Authorisation Holders (MAH) Set up Fee and Annual MAH Operational Fee applicable to those MAH or Parallel Distributor legal entities who can demonstrate that they are a micro MAH in the relevant year.</p><p>There continues to be on-going efforts at a national and European level to ensure that fee models take into account the specific situation of small companies.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8119 more like this
HL8120 more like this
HL8121 more like this
star this property question first answered
less than 2018-06-05T16:09:16.757Zmore like thismore than 2018-06-05T16:09:16.757Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
908918
star this property registered interest false more like this
star this property date less than 2018-05-21more like thismore than 2018-05-21
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Diabetes: Medical Equipment more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what measures are in place to ensure equitable access to (1) insulin pumps, and (2) other diabetes technologies, across England. more like this
star this property tabling member printed
Lord Roberts of Llandudno more like this
star this property uin HL8080 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>Clinical commissioning groups (CCGs) are responsible for commissioning diabetes services to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population and are based on the available evidence and take into account national guidelines. This should include consideration of access to insulin pumps and other diabetes technologies for people with diabetes who might benefit from them.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-05T15:55:33.68Zmore like thismore than 2018-06-05T15:55:33.68Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
3691
unstar this property label Biography information for Lord Roberts of Llandudno more like this
909644
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Hepatitis: Prisoners more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have to ensure that all new prisoners are offered a test for hepatitis C and have rapid access to care. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL8139 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>Public Health England, Her Majesty’s Prison and Probation Service and NHS England introduced ‘opt-out’ testing for blood-borne viruses, including hepatitis C, in prisons in the first National Partnership Agreement published in 2013 with phased implementation through a series of pathfinder prisons in three successive phases. Full implementation across the whole adult prison estate in England was concluded in financial year 2017/18, as described in the 2015 Second National Partnership Agreement. A copy of the <em>National Partnership Agreement between: The National Offender Management Service, NHS England and Public Health England for the Co-Commissioning and Delivery of Healthcare Services in Prisons in England 2015-2016</em> is attached.</p><p>All new consenting eligible adult receptions to prisons in England are now offered a hepatitis C test on an opt-out basis within 72 hours of reception in accordance with published national guidance; this usually occurs at second reception health screening. The standard for patients testing positive for hepatitis C is referral to specialists for assessment within a maximum of 18 weeks from referral.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-05T16:05:41.83Zmore like thismore than 2018-06-05T16:05:41.83Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name national_partnership_agreement_commissioning-delivery-healthcare-prisons_2015.pdf more like this
star this property title National Partnership Agreement 2015-16 more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
908910
star this property registered interest false more like this
star this property date less than 2018-05-21more like thismore than 2018-05-21
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Surgical Mesh Implants more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have to extend the time allowed for cases of clinical negligence to be brought on behalf of women harmed by pelvic mesh; and what assessment they have made of the number of women so affected, and of their exposure to debilitating side-effects. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8072 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>There is currently no plan to extend the limit in medical negligence cases specifically for mesh-injured patients.</p><p>Under section 11 of the Limitation Act 1980 a patient is able to bring a claim for damages for clinical negligence against a trust or any other healthcare provider within three years from the date of injury. However, this can be longer if the patient is a child, when the three year period only begins on his/her eighteenth birthday; the patient has a mental disorder within the meaning of the Mental Health Act 1983 so as to be incapable of managing his/ her own affairs, when the three year period is suspended; or there was an interval before the patient realised or could reasonably have found out that he/she had suffered a significant injury possibly related to his/her treatment.</p><p>The ‘date of knowledge’ of an injury could be a number of years after the treatment. In recognition that there may be some cases where the prescribed period is inadequate, the Limitation Act 1980 also gives the court discretion to disapply the limitation period in respect of claims for personal injuries when it considers it just and equitable to do so.</p><p>NHS Digital’s <em>Retrospective Review of Surgery for Urogynaecological Prolapse and Stress Urinary Incontinence using Tape or Mesh</em>, found for mesh insertion procedures for urogynaecological prolapse, between 2008/09 to 2016/17, 27,016 patients had a reported mesh insertion procedure for urogynaecological prolapse. There were only three reported readmissions for a removal procedure within 30 days of the identified insertion procedure. For patients who had a removal procedure more than 30 days after their initial insertion, the highest rate of readmissions occurs in the reporting year following the insertion. Patients who had an insertion in 2008/09 had a removal rate of 3.9 patients per 1,000 in 2009/10, but for patients who had an insertion in 2015/16, their removal rate was lower at 1.8 patients per 1,000 in 2016/17. The rate fluctuates for patients who had an insertion in the intervening reporting years. A summary of the report is attached.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-05T16:08:18.897Zmore like thismore than 2018-06-05T16:08:18.897Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name Retrospective_Review_of_Surgery.pdf more like this
star this property title Retrospective Review of Surgery more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
909642
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Hepatitis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what steps they are taking to ensure that the NHS England target of eliminating hepatitis C by 2025 is reached. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL8137 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>NHS England has embarked on a new procurement exercise that invites industry to support the plans to tackle hepatitis C as part of a longer term drug procurement contract. This procurement exercise was officially launched in March 2018. The conclusion of assessment of proposals is planned for September 2018 and NHS England anticipates the new procurement approach will be implemented from 1 October 2018. The aim of the strategic procurement is to accelerate whole systems action to reduce hepatitis C prevalence and incidence. If successful, the ambition is to support the elimination of hepatitis C as a public health threat earlier than the World Health Organization (WHO) goal of 2030 and as soon as 2025.</p><p>Public Health England who lead on hepatitis C surveillance will ensure that achievements against the WHO targets in England are tracked. The National Strategic Group for Viral Hepatitis will continue to bring together stakeholders to discuss and share individual and collective actions underway to contribute to these goals.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN HL8136 more like this
star this property question first answered
less than 2018-06-05T15:58:52.677Zmore like thismore than 2018-06-05T15:58:52.677Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
909645
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Hepatitis: Prisoners more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what steps they intend to take to ensure that all prisoners in England with hepatitis C can receive the treatment they require, including if they are moved between prisons or reach the end of their sentence mid-treatment. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL8140 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>People in prison diagnosed with hepatitis C virus infection which requires treatment should be referred to specialists for assessment within a maximum of 18 weeks from referral.</p><p>Specialist care for hepatitis C patients diagnosed in prison is generally provided as an in-reach, consultant led service linked to the local Operational Delivery Network (ODN) and supported by a prison nurse or general practitioner with a special interest in hepatitis C.</p><p>ODNs work with prison healthcare providers and NHS England commissioners to improve care pathways between prisons and the community. Treatment using new Directly Acting Antiviral medication can often be started and completed within one period of incarceration. If a patient is moved to another prison, the receiving prison healthcare team can access their records via the prison health informatics system ensuring continuity of care following patient transfer to another prison. If a prisoner is discharged back to the community before the end of their treatment, prison healthcare teams ensure that the patient is registered with a general practice and can provide a care summary record to support continuity of care.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-05T16:04:53.54Zmore like thismore than 2018-06-05T16:04:53.54Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
909641
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Hepatitis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what steps they intend to take to ensure that there is a comprehensive and measurable hepatitis C elimination plan in place, with clear lines of accountability, to achieve the NHS England 2025 elimination goal. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL8136 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>NHS England has embarked on a new procurement exercise that invites industry to support the plans to tackle hepatitis C as part of a longer term drug procurement contract. This procurement exercise was officially launched in March 2018. The conclusion of assessment of proposals is planned for September 2018 and NHS England anticipates the new procurement approach will be implemented from 1 October 2018. The aim of the strategic procurement is to accelerate whole systems action to reduce hepatitis C prevalence and incidence. If successful, the ambition is to support the elimination of hepatitis C as a public health threat earlier than the World Health Organization (WHO) goal of 2030 and as soon as 2025.</p><p>Public Health England who lead on hepatitis C surveillance will ensure that achievements against the WHO targets in England are tracked. The National Strategic Group for Viral Hepatitis will continue to bring together stakeholders to discuss and share individual and collective actions underway to contribute to these goals.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN HL8137 more like this
star this property question first answered
less than 2018-06-05T15:58:52.613Zmore like thismore than 2018-06-05T15:58:52.613Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
909624
star this property registered interest false more like this
star this property date less than 2018-05-22more like thismore than 2018-05-22
star this property answering body
Department of Health and Social Care more like this
unstar this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Drugs: Marketing more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether they intend to hold discussions with the UK Medicines Verification Organisation about the need to ensure that the (1) set up, and (2) annual operational, fees paid by companies who are Marketing Authorisation Holders are proportional to the size of those companies. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8119 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer remove filter
star this property answer text <p>SecurMed, the United Kingdom’s National Medicines Verification Organisation, is responsible for the fee model and level of fees. In their supervisory capacity, the Department and the Medicines and Healthcare products Regulatory Agency have been involved in discussions with SecurMed to challenge and seek to influence the pricing model to ensure that the UK’s fee structure is fair and proportionate.</p><p>The European Commission has confirmed that the fee model being used by SecurMed is in line with the majority of other National Medicines Verification Organisations across the European Union.</p><p>However, in light of feedback on the potential impact of the proposed level of fees for smaller companies, SecurMed has announced an annual fee waiver scheme for the Marketing Authorisation Holders (MAH) Set up Fee and Annual MAH Operational Fee applicable to those MAH or Parallel Distributor legal entities who can demonstrate that they are a micro MAH in the relevant year.</p><p>There continues to be on-going efforts at a national and European level to ensure that fee models take into account the specific situation of small companies.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8118 more like this
HL8120 more like this
HL8121 more like this
star this property question first answered
less than 2018-06-05T16:09:16.803Zmore like thismore than 2018-06-05T16:09:16.803Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this